Literature DB >> 15243086

Antigenic evidence of prevalence and diversity of Mycobacterium tuberculosis arabinomannan.

Aharona Glatman-Freedman1, Arturo Casadevall, Zongdong Dai, William R Jacobs, Anping Li, Sheldon L Morris, Josepine Anne D Navoa, Sajida Piperdi, John B Robbins, Rachel Schneerson, J Reid Schwebach, Michael Shapiro.   

Abstract

Arabinomannan (AM) is a polysaccharide of the mycobacterial capsule. The capsular polysaccharides of various microorganisms are diverse, and this diversity is important for classification of organisms into serotypes and vaccine development. In the present study we examined the prevalence and diversity of AM among Mycobacterium tuberculosis strains using four AM-binding monoclonal antibodies (MAbs). One of these MAbs, MAb 9d8, is known to bind to AM specifically. By whole-cell enzyme-linked immunosorbent assay (ELISA), the AM recognized by MAb 9d8 was detected on the surfaces of 9 of 11 strains, while 2 strains showed no reactivity with MAb 9d8. However, the AM recognized by MAb 9d8 was found in the culture supernatants of all 11 M. tuberculosis strains tested, as demonstrated by capture ELISA. Other AM-binding MAbs reacted both with the surfaces and with the culture supernatants of all 11 strains. Mice immunized with an experimental AM-recombinant Pseudomonas aeruginosa exoprotein A (rEPA) conjugate vaccine had an increased antibody response to AM and a moderate reduction in the numbers of CFU in their organs 7 days after challenge. Our results indicate that AM was detected in all M. tuberculosis strains tested, with differences in epitope distributions of certain strains. In addition, our results suggest that an experimental AM-rEPA vaccine has a moderate effect on the numbers of CFU in organs early after infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15243086      PMCID: PMC446310          DOI: 10.1128/JCM.42.7.3225-3231.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   11.677


  22 in total

1.  Immunosuppression by mycobacterial arabinomannan.

Authors:  J J Ellner; T M Daniel
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

2.  Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli.

Authors:  S W Hunter; H Gaylord; P J Brennan
Journal:  J Biol Chem       Date:  1986-09-15       Impact factor: 5.157

3.  Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.

Authors:  C L Trotter; M E Ramsay; E B Kaczmarski
Journal:  Commun Dis Public Health       Date:  2002-09

4.  Lipoarabinomannan of Mycobacterium tuberculosis. Capping with mannosyl residues in some strains.

Authors:  D Chatterjee; K Lowell; B Rivoire; M R McNeil; P J Brennan
Journal:  J Biol Chem       Date:  1992-03-25       Impact factor: 5.157

5.  Expression of a Mycobacterium tuberculosis arabinomannan antigen in vitro and in vivo.

Authors:  J R Schwebach; A Casadevall; R Schneerson; Z Dai; X Wang; J B Robbins; A Glatman-Freedman
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

Review 6.  Prospects for better tuberculosis vaccines.

Authors:  H L Collins; S H Kaufmann
Journal:  Lancet Infect Dis       Date:  2001-08       Impact factor: 25.071

Review 7.  Advances in antibody-mediated immunity against Mycobacterium tuberculosis: implications for a novel vaccine strategy.

Authors:  Aharona Glatman-Freedman
Journal:  FEMS Immunol Med Microbiol       Date:  2003-10-24

8.  Molecular composition of the outermost capsular material of the tubercle bacillus.

Authors:  A Ortalo-Magné; M A Dupont; A Lemassu; A B Andersen; P Gounon; M Daffé
Journal:  Microbiology       Date:  1995-07       Impact factor: 2.777

9.  Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis.

Authors:  Beston Hamasur; Melles Haile; Andrzej Pawlowski; Ulf Schröder; Ann Williams; Graham Hatch; Graham Hall; Philip Marsh; Gunilla Källenius; Stefan B Svenson
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

10.  Specificity and diversity of antibodies to Mycobacterium tuberculosis arabinomannan.

Authors:  Josephine Anne D Navoa; Suman Laal; Liise-Anne Pirofski; Gary R McLean; Zhongdong Dai; John B Robbins; Rachel Schneerson; Arturo Casadevall; Aharona Glatman-Freedman
Journal:  Clin Diagn Lab Immunol       Date:  2003-01
View more
  19 in total

1.  Comparative evaluation of profiles of antibodies to mycobacterial capsular polysaccharides in tuberculosis patients and controls stratified by HIV status.

Authors:  Xian Yu; Rafael Prados-Rosales; Elisabeth R Jenny-Avital; Katherine Sosa; Arturo Casadevall; Jacqueline M Achkar
Journal:  Clin Vaccine Immunol       Date:  2011-12-14

2.  Correlation between serum and plasma antibody titers to mycobacterial antigens.

Authors:  Michael Siev; Xian Yu; Rafael Prados-Rosales; Frank T Martiniuk; Arturo Casadevall; Jacqueline M Achkar
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

Review 3.  Do CD1-restricted T cells contribute to antibody-mediated immunity against Mycobacterium tuberculosis?

Authors:  Mark L Lang; Aharona Glatman-Freedman
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

Review 4.  Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis.

Authors:  Jacqueline M Achkar; Rafael Prados-Rosales
Journal:  Curr Opin Immunol       Date:  2018-04-12       Impact factor: 7.486

5.  Capsular glycan recognition provides antibody-mediated immunity against tuberculosis.

Authors:  Tingting Chen; Caroline Blanc; Yanyan Liu; Elise Ishida; Sarah Singer; Jiayong Xu; Maju Joe; Elizabeth R Jenny-Avital; John Chan; Todd L Lowary; Jacqueline M Achkar
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

6.  The Type of Growth Medium Affects the Presence of a Mycobacterial Capsule and Is Associated With Differences in Protective Efficacy of BCG Vaccination Against Mycobacterium tuberculosis.

Authors:  Rafael Prados-Rosales; Leandro J Carreño; Brian Weinrick; Ana Batista-Gonzalez; Aarona Glatman-Freedman; Jiayong Xu; John Chan; William R Jacobs; Steven A Porcelli; Arturo Casadevall
Journal:  J Infect Dis       Date:  2016-04-18       Impact factor: 5.226

Review 7.  The Mycobacterium tuberculosis capsule: a cell structure with key implications in pathogenesis.

Authors:  Rainer Kalscheuer; Ainhoa Palacios; Itxaso Anso; Javier Cifuente; Juan Anguita; William R Jacobs; Marcelo E Guerin; Rafael Prados-Rosales
Journal:  Biochem J       Date:  2019-07-18       Impact factor: 3.857

Review 8.  Antibody-mediated immunity against tuberculosis: implications for vaccine development.

Authors:  Jacqueline M Achkar; Arturo Casadevall
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

Review 9.  The protective role of antibody responses during Mycobacterium tuberculosis infection.

Authors:  F Abebe; G Bjune
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

10.  Monoclonal antibodies to Mycobacterium tuberculosis CDC 1551 reveal subcellular localization of MPT51.

Authors:  Ban Al-Sayyed; Sajida Piperdi; Xinni Yuan; Anping Li; Gurdyal S Besra; William R Jacobs; Arturo Casadevall; Aharona Glatman-Freedman
Journal:  Tuberculosis (Edinb)       Date:  2007-09-19       Impact factor: 3.131

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.